Iovance updates corporate presentation; guides FY26 revenue $350M-$370M, Q2 $86M-$88M

IOVANCE BIOTHERAPEUTICS, INC.

Q2 2026 revenue guidance of $86M-$88M; FY26 revenue guidance $350M-$370M; ~45% YoY quarterly growth.
Amtagvi commercial launch: >90 treatment centers, >1,500 patients treated; 5-year durability data: 31.4% ORR, 19.7% OS.
Lifileucel in NSCLC: 25.6% ORR, mDOR not reached at 25.4 months; Fast Track Designation; potential launch 2H27.
Soft tissue sarcoma Phase 2 registrational trial to commence 2Q 2026; 50% ORR in early data.
Cash $319M as of 3/31/26; manufacturing capacity up to 5K patients/year; broad payer coverage.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.